Is Anthem Bioscienc overvalued or undervalued?

As of August 29, 2025, Anthem Bioscienc is considered very expensive with a PE ratio of 90.82 and other high valuation metrics, indicating it is overvalued compared to peers, despite a recent positive return of 4.51%.

As of 29 August 2025, the valuation grade for Anthem Bioscienc has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 90.82, a Price to Book Value of 18.59, and an EV to EBITDA ratio of 65.82. These ratios are considerably higher than its peers, such as Sun Pharma with a PE of 33.34 and Divi's Lab at 70.28, both of which are categorized as expensive or very expensive.<BR><BR>In comparison to other companies in the pharmaceuticals and biotechnology sector, Anthem Bioscienc's high valuation metrics suggest that investors are paying a premium for its stock. The PEG ratio is notably at 0.00, which raises concerns about growth expectations not being met. While the stock has shown a positive return of 4.51% over the past month compared to a decline in the Sensex, the overall valuation still points to an overvaluation scenario.

How has been the historical performance of Anthem Bioscienc?

Anthem Bioscienc experienced significant growth from March 2024 to March 2025, with net sales rising to 1,844.55 Cr and profit after tax increasing to 451.26 Cr. Key metrics such as operating profit and cash flow also improved, reflecting strong financial performance.

Answer:<BR>The historical performance of Anthem Bioscienc shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Anthem Bioscienc reported net sales of 1,844.55 Cr in March 2025, an increase from 1,419.37 Cr in March 2024. The total operating income also rose to 1,844.55 Cr from 1,419.37 Cr, while total expenditure increased to 1,173.72 Cr from 914.40 Cr. This led to an operating profit (PBDIT) of 756.56 Cr, up from 568.67 Cr the previous year. Profit before tax reached 656.87 Cr, compared to 477.32 Cr in the prior year, resulting in a profit after tax of 451.26 Cr, which was higher than 367.31 Cr in March 2024. The earnings per share increased to 8.07 from 6.57, and the operating profit margin improved slightly to 36.37% from 35.58%. On the balance sheet, total assets grew to 2,789.64 Cr from 2,356.72 Cr, while total liabilities also increased to 2,789.64 Cr from 2,356.72 Cr. The cash flow from operating activities saw a notable rise to 418.00 Cr from 140.00 Cr, contributing to a net cash inflow of 132.00 Cr, reversing the outflow of 158.00 Cr in the previous year. Overall, Anthem Bioscienc demonstrated robust growth in sales, profits, and cash flow, indicating a strong financial performance.

Why is Anthem Bioscienc falling/rising?

As of 21-Dec, Anthem Biosciences Ltd's stock price is currently 678.85, reflecting a 1.49% increase today. Despite a recent decline of 2.90% over the past week, the stock has gained 5.58% over the past month, although investor participation has significantly decreased.

As of 21-Dec, Anthem Biosciences Ltd's stock price is rising, currently at 678.85, with a change of 9.95 (1.49%) upward. The stock has shown positive performance today, outperforming its sector by 0.74%. Additionally, it has been gaining for the last two days, with a total increase of 2.19% during this period. The stock reached an intraday high of Rs 683.45, reflecting a 2.18% increase at that point.<BR><BR>Despite these positive movements, it is important to note that the stock has experienced a decline of 2.90% over the past week, while the benchmark Sensex has only decreased by 0.40%. However, over the past month, the stock has performed well, increasing by 5.58%, while the Sensex has slightly declined by 0.30%. <BR><BR>The stock's current price is higher than its 20-day moving averages but lower than its 5-day, 50-day, 100-day, and 200-day moving averages. This indicates some volatility in its recent performance. Furthermore, there has been a significant drop in investor participation, with delivery volume falling by 50.5% against the 5-day average, which could impact future price movements. Nonetheless, the stock remains liquid enough for trading, based on its average traded value.

Why is Anthem Bioscienc falling/rising?

As of 22-Dec, Anthem Biosciences Ltd's stock price is at 680.70, showing a slight increase of 0.2% but underperforming the sector. Despite a recent positive trend over three days, declining investor participation and mixed moving averages suggest a cautious outlook.

As of 22-Dec, Anthem Biosciences Ltd's stock price is currently at 680.70, reflecting a slight increase of 1.35 (0.2%). Despite this modest rise, the stock has underperformed compared to the sector today, with a performance lag of -0.45%. Over the past three days, the stock has shown a positive trend, gaining 2.47% during this period. However, it has also experienced a decline in investor participation, with delivery volume dropping by 81.27% compared to the five-day average, indicating reduced trading activity.<BR><BR>In terms of moving averages, the stock is currently higher than its 20-day moving average but lower than the 5-day, 50-day, 100-day, and 200-day moving averages. This suggests that while there has been some recent upward movement, it may not be strong enough to indicate a sustained upward trend. Overall, while the stock has seen a slight increase today, the combination of underperformance relative to the sector and falling investor participation may contribute to a cautious outlook.

Why is Anthem Biosciences Ltd falling/rising?

As of 23-Dec, Anthem Biosciences Ltd's stock price is declining, currently at 667.00, reflecting a 2.01% decrease and notable underperformance compared to its sector. Investor participation has dropped significantly, indicating reduced trading interest and a weakening momentum.

As of 23-Dec, Anthem Biosciences Ltd's stock price is falling, currently at 667.00, which reflects a decrease of 13.7 or 2.01%. This decline is notable as the stock has underperformed its sector by 1.8% today and has experienced a trend reversal after three consecutive days of gains. The stock reached an intraday low of Rs 665.5, marking a decrease of 2.23%. <BR><BR>Additionally, investor participation has decreased significantly, with delivery volume dropping by 85.96% compared to the 5-day average, indicating reduced trading interest. While the stock is above its 20-day moving averages, it is below the 5-day, 50-day, 100-day, and 200-day moving averages, suggesting a weakening momentum. Overall, these factors contribute to the current decline in the stock price of Anthem Biosciences Ltd.

Which are the latest news on Anthem Bioscienc?